Clinical trial watch: Reports from the AASLD Liver Meeting®, Boston, November 2014

Journal of Hepatology

Volumn 62, Issue 5, 2015, Pages 1196-1203

  Londoño, María Carlota ^a   Abraldes, Juan G ^b   Altamirano, José ^c   Decaens, Thomas ^d   Forns, Xavier ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITY OF ALBERTA   (Canada)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

Hepatitis; Hepatocellular carcinoma; NASH; Portal hypertension

Indexed keywords

ANTIBIOTIC AGENT; ANTIVIRUS AGENT; DIRECT ACTING ANTIVIRAL AGENT; INTERFERON; RIBAVIRIN; TERLIPRESSIN; UNCLASSIFIED DRUG;

ALCOHOL LIVER DISEASE; ANTIBIOTIC THERAPY; ANTIVIRAL THERAPY; ARTICLE; BACTERIAL PERITONITIS; BARIATRIC SURGERY; CHILD PUGH SCORE; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL (TOPIC); CRYOABLATION; DECOMPENSATED LIVER CIRRHOSIS; DISEASE SEVERITY; ECHOGRAPHY; FOLLOW UP; GENOTYPE; GRAFT RECIPIENT; HEPATIC ENCEPHALOPATHY; HEPATITIS B; HEPATITIS C; HEPATORENAL SYNDROME; HOSPITAL INFECTION; HUMAN; LIFESTYLE; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER FUNCTION; LIVER GRAFT; MULTICENTER STUDY (TOPIC); NONALCOHOLIC FATTY LIVER; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; SCREENING; SEPTIC SHOCK; TREATMENT FAILURE; UNITED STATES; VIRUS HEPATITIS; CLINICAL TRIAL (TOPIC); DISEASE MANAGEMENT; LIVER DISEASES; ORGANIZATION;

CLINICAL TRIALS AS TOPIC; CONGRESSES AS TOPIC; DISEASE MANAGEMENT; HUMANS; LIVER DISEASES;

EID: 84927800135     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2015.01.028     Document Type: Review

References (56)

1. D. Dieterich, B. Bacon, S. Flamm, K. Knowdley, S. Milligan, and N. Tsai Evaluation of sofosbuvir and simeprevir-based regimens in the TRIO network: academic and community treatment of a real-world, heterogeneous population Hepatology 60 2014 220A [Abstract # 46]
2. D. Jenssen, J. O'Leary, P.J. Pockros, K.E. Sherman, P. Kwo, and M.E. Mailliard Safety and efficacy of sofosbuvir-containing regimens for hepatitis C: real-world experience in a diverse, longitudinal observational cohort Hepatology 60 2014 219A [Abstract # 45]
3. M. Bourliere, J. Bronowicki, V. de Ledinghen, C. Hezoce, F. Zoulim, and P. Mathirin Ledipasvir/sofosbuvir fixed dose combination is safe and efficacious in cirrhotic patients who have previously failed protease-inhibitor based triple therapy Hepatology 60 2014 1270A [Abstract LB-6]
4. D. Wyles, P.J. Pockros, J.C. Yang, Y. Zhu, P.S. Pang, and J. McHutchinson Retreatment of patients who failed prior sofosbuvir-based regimens with all oral fixed-dose combination ledipasvir/sofosbuvir plus ribavirin for 12 weeks Hepatology 60 2014 317A [Abstract # 235]
5. D. Nelson, J. Cooper, J. Lalezari, E. Lawitz, P.J. Pockros, and N. Gitlin All-oral 12-week combination treatment with Daclatasvir and sofosbuvir in patients infected with HCV genotype 3: ALLY-3 phase 3 study Hepatology 60 2014 1268A [Abstract LB-3]
6. S. Zeuzem, G.M. Dusheiko, R. Salupere, A. Mangia, R. Flisiak, and R.H. Hyland Sofosbuvir and ribavirin in HCV genotypes 2 and 3 N Engl J Med 370 2014 1993 2001
7. M. Bourliere, M. Sulkowski, M. Omata, S. Zeuzem, J. Feld, and E. Lawitz An integrated safety and efficacy analysis of >500 patients with compensated cirrhosis treated with ledipasvir/sofosbuvir with or without ribavirin Hepatology 60 2014 239A [Abstract # 82]
8. S. Flamm, G. Everson, M. Charlton, J. Denning, S. Arterburn, and T. Brandt-Sarif Ledipasvir/sofosbuvir with ribavirin for the treatment of HCV in patients with decompensated cirrhosis: preliminary results of a prospective, multicenter study Hepatology 60 2014 320A [Abstract # 239]
9. K.R. Reddy, G. Everson, S. Flamm, J. Denning, S. Arterburn, and T. Brandt-Sarif Ledipasvir/sofosbuvir with ribavirin for the treatment of HCD in patients with post-transplant recurrence: preliminary results of a prospective multicenter study Hepatology 60 2014 200A [Abstract # 8]
10. P.S. Mantry, P. Kwo, E. Coakley, H.S. Te, H.E. Vargas, and R.S. Brown High sustained virologic response rates in liver transplant recipients with recurrent HCV genotype 1 infection receiving ABT-450/r/ombitasvir+dasabuvir plus ribavirin Hepatology 60 2014 298A [Abstract # 198]
11. S. Pungpapong, K.T. Werner, B. Aqel, M.D. Leise, J.L. Murphy, and T.M. Henry Multicenter experience using sofosbuvir and simeprevir with/without ribavirin to treat HCV genotype 1 after liver transplantation Hepatology 60 2014 201A [Abstract # 9]
12. A.J. Muir, F. Poordad, J. Lalezari, G. Everson, G.J. Dore, and P. Kwo All oral, fixed-dose combination therapy with Daclatasvir/Asunaprevir/Beclabuvir ± Ribavirin for chronic genotype 1 infection and compensated cirrhosis: UNITY-2 phase 3 SVR12 results Hepatology 60 2014 1267A [Abstract LB-2]
13. F. Poordad, W. Sievert, L. Mollison, N. Brau, J.M. Levin, and T.E. Sepe All oral, fixed-dose combination therapy with Daclatasvir/Asunaprevir/Beclabuvir for non-cirrhotic patients with chronic genotype 1 infection: UNITY-1 phase 3 SVR12 results Hepatology 60 2014 1271A [Abstract LB-7]
14. M. Sulkowski, C. Hezoce, J. Gerstof, J.M. Vierling, J. Mallolas, and S. Pol Efficacy and safety of MK-5172 + MK-8742 ± ribavirin in HCV mono-infected and HIV/HCV co-infected treatment-naïve, non-cirrhotic patients with hepatitis C virus genotype 1 infection: the C-WORTHY study (Final results, Parts A and B) Hepatology 60 2014 318A [Abstract # 236]
15. E. Lawitz, E. Gane, B. Pearlman, E. Tam, W. Ghesquiere, and D. Guyader Efficacy and safety of MK-5172 and MK-8742 ± ribavirin in hepatitis C genotype 1 infected patients with cirrhosis or previous null response: final results of the C-WORTHY Study (Parts A and B) Hepatology 60 2014 296A [Abstract # 196]
16. E. Lawitz, F. Poordad, J.A. Gutierrez, B. Evans, P. Hwang, and M. Robertson C-SWIFT: MK-5172 + MK-8742 + Sofosbuvir in treatment-naive patients with hepatitis C virus genotype 1 infection, with and without cirrhosis, for durations of 4, 6, or 8 weeks Hepatology 60 2014 1286A [Abstract LB-33]
17. P. Marcellin, S. Ahn, X. Ma, F.A. Caruntu, W. Tak, and M. Elkashab HBsAg loss with tenofovir disoproxil fumarate (TDF) plus peginterferon alfa-2a (PEG) in chronic hepatitis B (CHB): results of a global randomized controlled trial Hepatology 60 2014 294A [Abstract # 193]
18. P. Angeli, A. Sanyal, S. Moller, C. Alessandria, A. Gadano, and R. Kim Current limits and future challenges in the management of renal dysfunction in patients with cirrhosis: report from the International Club of Ascites Liver Int 33 2013 16 23
19. P. Gines Hepatorenal syndrome, pharmacological therapy, and liver transplantation Liver Transpl 17 2011 1244 1246
20. S.V. Sagi, S. Mittal, K.S. Kasturi, and G.K. Sood Terlipressin therapy for reversal of type 1 hepatorenal syndrome: a meta-analysis of randomized controlled trials J Gastroenterol Hepatol 25 2010 880 885
21. T. Boyer, A. Sanyal, F. Wong, T. Frederick, J. Lake, and J.G. O'Leary Initial report of a large, randomized, double blind, placebo-controlled, phase 3 trial of terlipressin plus albumin for the treatment of type 1hepatorenal syndrome (HRS-1): the REVERSE study Hepatology 60 2014 255A [Abstract # 114]
22. A. Sanyal, T. Boyer, T. Frederick, F. Regenstein, L. Rossaro, and V. Araya Reversal of hepatorenal syndrome type 1 (HRS-1) with terlipressin plus albumin versus placebo plus albumin - Not all responses are created equal - An analysis of the REVERSE and OT-0401 trials Hepatology 60 2014 322A [Abstract # 241]
23. A.J. Sanyal, T. Boyer, G. Garcia-Tsao, F. Regenstein, L. Rossaro, and B. Appenrodt A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome Gastroenterology 134 2008 1360 1368
24. P. Gines, J. Fernandez, F. Durand, and F. Saliba Management of critically-ill cirrhotic patients J Hepatol 56 2012 S13 S24
25. A.K. Choudhury, C. Vashishtha, D. Saini, S. Kumar, and S.K. Sarin A prospective open label randomized noninferiority trial to compare the efficacy and safety of monotherapy with noradrenaline and terlipressin in patients of cirrhosis with septic shock admitted to the Intensive care unit (NCT01836224) Hepatology 60 2014 254A [Abstract # 113]
26. J. Fernandez, J. Acevedo, M. Castro, O. Garcia, C.R. de Lope, and D. Roca Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study Hepatology 55 2012 1551 1561
27. P. Tandon, A. Delisle, J.E. Topal, and G. Garcia-Tsao High prevalence of antibiotic-resistant bacterial infections among patients with cirrhosis at a US liver center Clin Gastroenterol Hepatol 10 2012 1291 1298
28. R. Jalan, J. Fernandez, R. Wiest, B. Schnabl, R. Moreau, and P. Angeli Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013 J Hepatol 60 2014 1310 1324
29. S. Piano, F. Salinas, F. Morando, M. Cavallin, A. Rmano, and S. Rosi The empirical antibiotic treatment of nosocomial spontaneous bacterial peritonitis in patients with decompensated liver cirrhosis: results of a randomized controlled clinical trial Hepatology 60 2014 57AA [Abstract # 574]
30. A. Jindal, and S.K. Sarin A randomized trial of 'Imipenem versus Cefepime' in difficult to treat spontaneous bacterial peritonitis (SBP) and to evaluate the risk factors for treatment failure Hepatology 60 2014 279A [Abstract # 162]
31. R.K. Dhiman, B.S. Rana, S. Agrawal, A. Garg, M. Chopra, and K.K. Thumburu Efficacy and safety of a probiotic preparation in the secondary prophylaxis of hepatic encephalopathy in cirrhotic patients: final results of a double blind, randomized, placebo controlled study Hepatology 60 2014 278A [Abstract # 159]
32. J. Vlachogiannakos, P. Vasianopoulou, N. Viazis, M. Chroni, T. Voulgaris, and S.D. Ladas The role of probiotics in the treatment of minimal hepatic encephalopathy. A prospective, randomized, placebo-controlled, double-blind study Hepatology 60 2014 376A [Abstract # 353]
33. J.G. Abraldes, I. Tarantino, J. Turnes, J.C. Garcia-Pagan, J. Rodes, and J. Bosch Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis Hepatology 37 2003 902 908
34. C. Gluud, J. Brok, Y. Gong, and R.L. Koretz Hepatology may have problems with putative surrogate outcome measures J Hepatol 46 2007 734 742
35. A. Berzigotti, A. Albillos, C. Villanueva, J. Genesca, A. Ardevol, and S. Augustin Lifestyle intervention by a 16-week programme of supervised diet and physical exercise ameliorates portal hypertension in patients with cirrhosis and obesity: the SportDiet study Hepatology 60 2014 253A [Abstract # 110]
36. L. Zenith, N. Meena, A. Ramadi, M. Yavari, A. Harvey, and M. Carbonneau Eight weeks of exercise training increases aerobic capacity and muscle mass and reduces fatigue in patients with cirrhosis Clin Gastroenterol Hepatol 12 2014 e1922
37. M.A. Macias-Rodriguez, A. Torre, H. Ilarraza-Lo-meli, A. Ruiz-Margain, O. Garcia-Flores, and A. Duarte-Rojo Changes on hepatic venous pressure gradient induced by a physical exercise program in cirrhotic patients: a randomized open clinical trial Hepatology 60 2014 246A [Abstract # 96]
38. V. Ratziu, S. Bellentani, H. Cortez-Pinto, and G. Marchesini A position statement on NAFLD/NASH based on the EASL 2009 special conference J Hepatol 53 2010 372 384
39. N. Chalansani, Z. Younossi, J. Lavine, A. Dielh, E. Brunt, and K. Cusi The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology Gastroenterology 142 2012 1592 1609
40. S. Yatsuli, E. Hashimoto, M. Tobari, M. Taniai, K. Tokushige, and K. Shiratori Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C J Gastroenterol Hepatol 24 2009 248 254
41. P. Angulo, D. Kleiner, S. Dam-Larsen, L. Adams, B. Einar, and P. Charatcharoenwitthaya The prognostic relevance of liver histology features in nonalcoholic fatty liver disease: the PRELHIN study Hepatology 60 2014 226A [Abstract # 59]
42. S. Harrison, N. Chalasani, E. Lawitz, S. Marri, M. Noureddin, and A. Sanyal Early phase 1 clinical trial results of GR-MD-02, a galectin-3 inhibitor, in patients having non-alcoholic steatohepatitis (NASH) with advanced fibrosis Hepatology 60 2014 225A [Abstract # 57]
43. G. Lassailly, R. Caiazzo, D. Buob, M. Pigeyre, H. Verkindt, and V. Raverdy Effects of bariatric surgery on severe liver injury in morbid obese patients with proven NASH: a prospective study Hepatology 60 2014 305A [Abstract # 213]
44. J. Altamirano, and R. Bataller Alcoholic liver disease: pathogenesis and new targets for therapy Nat Rev Gastroenterol Hepatol 8 2011 491 501
45. E. Cabré, P. Rodríguez-Iglesias, J. Caballería, J. Quer, J. Sánchez-Lombraña, and A. Parés Short- and long-term outcome of severe alcohol-induced hepatitis treated with steroids or enteral nutrition: a multicenter randomized trial Hepatology 32 2000 36 42
46. C. Moreno, E. Trepo, A. Louvet, D. Degré, B. Bastens, and A. Hittelet Impact of intensive enteral nutrition in association with corticosteroids in the treatment of severe alcoholic hepatitis: a multicenter randomized controlled trial Hepatology 60 2014 269A [Abstract # 141]
47. M. Thursz, P. Richardson, M. Allison, A. Austin, M. Bowers, and C. Day Steroids or pentoxifylline for alcoholic hepatitis: results of the STOPAH trial Hepatology 60 2014 1267A [Abstract LB-1]
48. A. Jemal, F. Bray, M.M. Center, J. Ferlay, E. Ward, and D. Forman Global cancer statistics CA Cancer J Clin 61 2011 69 90
49. Z. Poh, C.Y. Lin, B. Goh, J. Chang, C. Tan, and L. Shen Real world risk score for hepatocellular carcinoma (RWS-HCC): development and external validation of a clinically practical score to identify low risk individuals Hepatology 60 2014 280A [Abstract # 164]
50. H.B. El-Serag Hepatocellular carcinoma N Engl J Med 365 2011 1118 1127
51. L.Y. King, H. Khalili, R.T. Chung, A.T. Chan, and E.S. Huang Diabetes mellitus is associated with an increased risk of HCC in a large prospective cohort with long term follow-up Hepatology 60 2014 281A [Abstract # 165]
52. D.S. Goldberg, J.D. Lewis, A. Valderama, R. Kamalakar, S. Babajanyan, and S.S. Sansgiry Hepatocellular carcinoma (HCC) surveillance among cirrhotic patients with commercial health insurance: national rates and determinants of surveillance Hepatology 60 2014 281A [Abstract # 166]
53. C. Wang, W. Bai, Z. Dong, Y. Lu, Z. Zeng, and M. Lou A multicenter randomized control trial of percutaneous cryoablation versus radiofrequency ablation therapy in patients with hepatocellular carcinoma Hepatology 60 2014 282A [Abstract # 168]
54. C. Su, P. Lee, T. Huo, Y. Huang, K. Lee, and H. Lin Antiplatelet therapy is associated with better prognosis in patients with hepatitis B virus-related hepatocellular carcinoma after resection surgery Hepatology 60 2014 198A [Abstract # 4]
55. N. Mehta, F.Y. Yao, J. Heimbach, D.M. Harnois, J.M. Burns, and D. Lee Short waiting time predicts early recurrence of hepatocellular carcinoma after liver transplantation: a multicenter study supporting the "ablate and wait" principle Hepatology 60 2014 446A [Abstract # 504]
56. N. Mehta, M. Sarkar, J. Guy, R.W. Osorio, C.T. Frenette, and W.B. Minteer Multicenter study of down-staging of hepatocellular carcinoma (HCC) to within Milan criteria before liver transplantation (LT) Hepatology 60 2014 253A [Abstract # 111]